February 20, 2025

A statement from the cooperative groups

February 14, 2025

From the group co-chairs of ECOG-ACRIN: A perspective on indirect costs (requires subscription)

February 6, 2025

“I was delighted when I saw the results. Positive phase 3 trials in glioma are a rarity.” David Schiff on the results of E3F05

January 17, 2025

The Winter 2025 advocacy blog Considering Clinical Trials is now available

January 16, 2025

Major breast cancer screening trial hits enrollment goal (features TMIST)

January 16, 2025

TMIST breast cancer screening trial reaches enrollment milestone, advancing precision screening techniques

January 14, 2025

Cellular therapies and novel targeted agents will shape the future of acute lymphoblastic leukemia management (mentions E1910)

January 10, 2025

Adjuvant tamoxifen reduces 15-year risk of recurrence in ‘good risk’ DCIS without radiation therapy (mentions E5194)

January 8, 2025

WATCH: A recent FDA approval of blinatumomab was supported by data from the E1910 trial

ECOG-ACRIN Cancer Research Group